Roche's Daniel O'Dea will become Gilead's chief executive
-
Last Update: 2021-02-26
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
, the current chief executive of Roche Pharmaceuticals, will become chief executive from March 1 next year, the company announced.replaces current chief executive John Milligan, who will resign at the end of 2018.Daniel has been head of Roche's pharmaceutical division since 2012 and previously served as head of the company's diagnostics division before joining the company in 1987.Commenting on the appointment,Gilead chairman John Martin said O'Dea was uniquely qualified to play a role in driving innovation in all aspects of the business, given his track record of success in high-tech and competitive treatments, a deep understanding of the changing healthcare environment around the world and a strong commitment.said Gregg Alton, who is currently chief patient officer, would take over as interim chief executive in early 2019 until O'Dea took over.commenting on O'Dea's departure, Severin Schwan, Chief Executive Officer of Roche, said, "He has had an outstanding 31-year career at Roche and has played a key role in bringing a wealth of innovative new drugs to patients." " (Compiled by this web)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
